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Overexpression of endothelial nitric oxide synthase
increases skeletal muscle blood flow and
oxygenation in severe rat hind limb ischemia
Lucy S. Brevetti, MD, David S. Chang, MD, Gale L. Tang, MD, Rajabrata Sarkar, MD, PhD, and
Louis M. Messina, MD, San Francisco, Calif
Objective: Although nitric oxide (NO) has a critical role in angiogenesis, the therapeutic potential of NO synthase
overexpression in severe ischemia remains undefined. We tested the hypothesis that overexpression of endothelial NO
synthase (eNOS) would improve tissue perfusion in severe hind limb ischemia.
Methods: Severe hind limb ischemia was induced in 122 adult male Sprague-Dawley rats. Ten days after the induction of
hind limb ischemia, vascular isolation and intraarterial delivery of an adenoviral vector encoding eNOS (AdeNOS), a
control adenoviral vector (AdE1), or phosphate-buffered saline solution (PBS) was performed. Skeletal muscle blood
flow, muscle oxygen tension, angiography, and immunohistochemistry for capillary counts were measured.
Results: Gene transfer of AdeNOS increased eNOS protein expression and enzyme activity. Two weeks after gene transfer,
skeletal muscle blood flow was fourfold higher in eNOS-transduced than in AdE1-transduced or PBS treated rats and was
similar to exercise-induced maximal flow in nonischemic muscle. eNOS overexpression increased muscle oxygen tension
in a titer-dependent fashion. This increase persisted 1 month after transduction, even though eNOS enzyme activity had
declined to normal levels. Angiography and capillary counts showed that eNOS overexpression increased the size and
number of collateral arteries, but did not significantly increase the capillary–muscle fiber ratio.
Conclusions: eNOS overexpression in an ischemic rat hind limb significantly increased skeletal muscle blood flow, muscle
oxygen tension, and collateral arteries (arteriogenesis). Furthermore, eNOS overexpression did not result in capillary
angiogenesis above control levels. These studies demonstrate the potential for eNOS overexpression as treatment for
severe limb ischemia in human beings. (J Vasc Surg 2003;38:820-6.)
Critical limb ischemia due to atherosclerotic occlusive
disease is a significant clinical problem that can lead to
disability and limb loss. Despite advances in surgical and
catheter-based limb revascularization, critical limb ischemia
still results in 150,000 major amputations annually.1 Con-
sequently there is intense interest in the development of
therapeutic angiogenesis to reverse the effects of critical
limb ischemia. This disease is a logical target for application
of therapeutic angiogenesis, because of easy accessibility of
the target tissue, ease in monitoring limb blood flow, and
lack of treatment options if surgical or percutaneous revas-
cularization is not feasible. A variety of peptide growth
factors induce therapeutic angiogenesis in experimental
models of hind limb ischemia2-4; vascular endothelial
growth factor (VEGF) has been the most widely studied.4-6
However, nitric oxide (NO), produced by endothelial
NO synthase (eNOS), has a critical role in angiogenesis.
For example, autocrine production of NO is essential for
endothelial cell proliferation and migration in vitro.7 Fur-
thermore, angiogenesis is impaired in eNOS knockout
mice.8 In addition, these mice are also resistant to VEGF-
induced angiogenesis,8 which suggests that the angiogenic
effect of VEGF depends on production of NO.9 Finally,
dietary supplementation with L-arginine, the NO precursor
substrate for eNOS, increases blood flow and improves
vasomotor tone in rabbit hind limb ischemia8 and corrects
the impaired angiogenesis induced by hypercholesterol-
emia in rat hind limb ischemia.10
NO is important for other reasons. Critical limb is-
chemia often occurs in patients with other disorders that
impair endothelial NO function, such as hypertension,
diabetes, smoking, and hyperlipidemia. Decreased NO syn-
thesis or activity in these disorders may be responsible for
impairment of collateral artery development and resultant
persistent tissue ischemia. These patients also may not
receive the full therapeutic benefit of angiogenic therapy,
which requires downstream activation of eNOS, such as
administration of VEGF, as evidenced by lack of effect of
VEGF on angiogenesis in eNOS knockout mice.8 For these
reasons, direct augmentation of eNOS activity is an attrac-
tive therapeutic target in patients with critical limb is-
chemia. We hypothesized that adenoviral overexpression of
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eNOS would induce arteriogenesis and increase skeletal
muscle blood flow and oxygen tension (PO2) in a rat model
of severe hind limb ischemia.
MATERIAL AND METHODS
Adenoviral vectors. All adenoviral vectors were first
generation (E1 and E3 region deleted) replication-incom-
petent vectors. The adenoviral vector encoding eNOS (Ad-
eNOS) contains the bovine endothelial NO synthase com-
plementary DNA driven by the Rous sarcoma virus
promoter,11 and was a generous gift of Dr Beverly L.
Davidson of the University of Iowa College of Medicine.
AdE1 contains the identical viral backbone without a trans-
gene. Propagation, purification, and storage of these vec-
tors were performed as described,12 and concentration of
adenoviral vectors was determined with standard plaque
assay techniques.12 Frozen vector stocks were thawed im-
mediately before use and diluted in sterile phosphate-buff-
ered saline solution (PBS) to achieve the indicated titers.
Rat hind limb ischemia model and adenoviral gene
transfer. One hundred twenty-two male Sprague-Dawley
rats (300-350 g; Simonsen, Gilroy, Calif) were used. Ani-
mals were housed in an environmentally controlled room
and were given food and water as desired. The care of
animals complied with the Guide for the Care and Use of
Laboratory Animals.
Rats were anesthetized by inhalation of 1% to 2% isoflu-
rane, and hind limb ischemia was created with ligation of
the left common iliac artery, external iliac artery, and fem-
oral artery, as described.12,13 Ten days after induction of
ischemia, gene transfer to the vasculature and skeletal myo-
cytes was accomplished with intraarterial injection of Ad-
eNOS or appropriate control solution during vascular iso-
lation of the hind limb, as described.14 In brief, tourniquet
isolation of the proximal thigh was used to prevent collat-
eral inflow or outflow. The left saphenous artery was can-
nulated, and blood in the vasculature was flushed out with
saline solution through a venotomy in the saphenous vein.
The venotomy was clamped temporarily, and 0.7 mL of
PBS or adenoviral vector was infused via the saphenous
artery. After a 30-minute dwell time the vein clamp was
removed, and vector was flushed out of the limb with 5 mL
of PBS, followed by ligation of the saphenous artery and
vein. This technique results in efficient adenoviral gene
transfer to hind limb capillary endothelium and skeletal
muscle, with minimal gene transfer in distant organs.14
eNOS immunoblotting and activity assay. Western
blotting and eNOS enzyme activity assays were performed
on homogenates of gastrocnemius muscle as previously.12
In brief, gastrocnemius muscle homogenates were pre-
pared, fractionated with sodium dodecylsulfate polyacryl-
amide gel electrophoresis (SDS-PAGE), and transferred to
nylon membranes for Western blotting. Rabbit polyclonal
antibody to eNOS (Transduction Laboratories, Lexington,
Ky) was used to probe membranes, and secondary detec-
tion was done with horseradish peroxidase–linked donkey
anti-rabbit antibody with chemiluminescent detection
(ECL Plus; Amersham Bioscience, Piscatawny, NJ). Den-
sitometry was determined with Scion Image (NIH Imag-
ing, Bethesda, Md). Nitric oxide synthase activity was
determined in gastrocnemius muscle homogenates on days
3, 14, and 30 after gene transfer, with a commercial assay
that measures conversion of radiolabeled arginine to citrul-
line (Calbiochem-Novabiochem Corp, San Diego, Calif)
according to the manufacturer’s instructions.12 Calcium-
dependent NO synthase activity (NOS-1, NOS-3) was
calculated by subtracting NOS activity measured without
calcium from total NOS activity, and is expressed as counts
per minute per milligram of protein.
Measurement of skeletal muscle blood flow and
(PO2). Rats were anesthetized 14 days after gene transfer,
and regional blood flow to the gastrocnemius muscle was
determined with fluorescent microspheres, as described.13
In brief, 4  105 polystyrene blue or yellow-green fluores-
cent 15-m-diameter microspheres (Triton Technology,
San Diego, Calif) were injected into the left ventricle.
Fluorescence in the gastrocnemius muscle was quantified
with spectrophotometry after processing tissue with potas-
sium hydroxide and 2-ethoxyethyl acetate. Blood flow rate
was calculated as milligrams per liter per minute per gram of
tissue. For measurement of skeletal muscle (PO2), rats were
anesthetized 14 and 30 days after gene transfer and their
gastrocnemius muscles were exposed. Licox Clark-type ox-
ygen and temperature probes (GMS, Keil-Mielkendorf,
Germany) were inserted into the muscle through 18-gauge
needles, and the sensors were positioned at the midportion
of the muscle. (PO2) and gastrocnemius muscle tempera-
ture were recorded every 1 to 3 minutes with the rats
breathing 100% oxygen until a plateau was reached (ap-
proximately 45 minutes) and then room air (21% oxygen)
until a plateau was noted (approximately 45 minutes).
Measurements were made on 100% oxygen to unmask
perfusion deficits in chronic ischemia, as described.15,16
Control values were determined in the right (nonischemic)
limbs of animals.
Immunohistochemistry. Immunohistochemical stain-
ing for eNOS protein was performed, as described,12 on
10-m frozen sections of gastrocnemius muscle, with a
mouse monoclonal antibody to human eNOS (Transduc-
tion Laboratories; cross-reacts with human, rat, and bovine
eNOS) at 1:250 dilution. Biotinylated goat anti-mouse
immunoglobulin G (IgG) was applied, followed by avidin-
biotin horseradish peroxidase complex, and colorimetric
detection was performed with 0.05% 3,3-diaminobenzi-
dine (DAB) tetrahydrochloride and 0.01% hydrogen per-
oxide. Capillary and arteriole counts were determined by
staining for the endothelial-specific antigen CD31 with a
monoclonal antibody to rat CD31 (Pharmigen, San Diego,
Calif). Sections were incubated overnight in 1:250 dilution
at 4°C, washed, and incubated for 60 minutes in biotinyl-
ated horse anti-mouse IgG, and colorimetric detection was
performed as described previously. Capillary and arteriole
density and capillary–muscle fiber ratio were determined by
a blinded observer examining the middle portion of sec-
tions at 400 magnification. To determine capillary and
arteriole densities, six random fields were counted in a box
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measuring 0.0625 mm2. Arterioles were differentiated
from capillaries by vessel wall thickness (greater than 1 cell
layer was consistent with an arteriole). To determine capil-
lary–muscle fiber ratio, capillaries and muscle fibers were
counted in five random muscle fiber bundles.
A bromodeoxyuridine (BrdU)–labeling and monoclo-
nal antibody detection kit (Roche Diagnostics Corp, Indi-
anapolis, Ind) was used to determine cellular proliferation.
Rats were injected intraperitoneally with BrdU (31 mg/kg)
24 hours and 12 hours before they were killed. Frozen
sections (10 m) were prepared from the gastrocnemius
and tibialis anterior muscles and the small intestine. In
brief, after fixation, peroxidase blocking with 0.3% hydro-
gen peroxide, and rinsing in tris-buffered saline solution
(TBS), the slides were incubated in 2N hydrocholoride for
30 minutes at room temperature. Slides were then rinsed
with TBS and blocked with avidin and biotin. The slides
were incubated with anti-BrdU mouse monoclonal anti-
body for 30 minutes at room temperature, and rinsed with
TBS. The slides were treated with a biotinylated secondary
antibody (horse anti-mouse [rat adsorbed]; Vector Labo-
ratories, Burlingame, Calif) followed by a streptavidin per-
oxidase conjugate, and developed with DAB chromogen.
The slides were counterstained with hematoxylin, dehy-
drated, and mounted. Slides from all groups were run in
parallel on the same day. Negative controls consisted of
similar sections treated in an identical manner but exclud-
ing the primary antibody. Positive controls consisted of the
intestinal mucosa of the same rats. Cellular proliferation
was quantified by counting BrdU-stained cells in six fields
per slide at 400 magnification.
Hindlimb angiography. Inasmuch as no significant
differences were noted in blood flow (Fig 1, A) or muscle
oxygenation (Fig 1, B) between rats receiving PBS or
AdE1, angiography was carried out on PBS-treated and
AdeNOS-treated animals 30 days after gene transfer. Rats
were anesthetized with 1% to 2% inhaled isoflurane. The
infrarenal abdominal aorta was ligated proximally and can-
nulated distally with a 20-gauge polyethylene catheter. The
hind limbs were exanguinated through a venotomy in the
inferior vena cava, with heparinized saline solution (10
U/mL). Barium sulfate (0.6 g/mL, 1.5 mL) was then
injected into the aortic catheter, and the vena cava was
ligated. The skin was removed from the rat hind limbs to
avert imaging the dermal vasculature. Images were ac-
quired with a single enveloped Kodak X-OMAT TL film
(Eastman Kodak, Dallas, Tex), with 500 mA, 50 kV, and
0.5 s exposure. Rats were killed before imaging. Images
were scored independently by three raters blinded to treat-
ment, who counted the number of vessels that crossed a
standardized 1  1-cm grid overlying the image within an
area of interest defined as the greater trochanter to the
distal femur. The number of vessels was divided by the lines
of the grid in the area of interest to produce an angioscore.
Statistical analysis. Mean and SEM values are re-
ported. Statistical analysis was performed with the Student
t test for two independent samples, and analysis of variance
for multiple group comparisons was performed with the
Fisher exact test for post-hoc analysis.
RESULTS
Gene transfer and expression of eNOS. Successful
adenoviral gene transfer and eNOS overexpression were
demonstrated with Western blotting, immunohistochem-
istry, and measurement of eNOS activity (Fig 2, A-C).
Fig 1. Effect of endothelial nitric oxide synthase (eNOS) overex-
pression on muscle blood flow and oxygen tension (PO2). A,
Skeletal muscle blood flow determined by microspheres 14 days
after gene transfer. Significant increase in encoding eNOS (AdeN-
OS)–treated rats. *P .05 vs other groups. B, Muscle PO2 (in mm
Hg) of normal and ischemic gastrocnemius muscles 14 and 30 days
after gene transfer with rats breathing room air. Animals received
the indicated titers of AdeNOS or control solutions as indicated.
Note dose-dependent increase in PO2 14 days after gene transfer
with AdeNOS treatment, which persisted at 30 days. C, Rats
breathing 100% oxygen to amplify perfusion differences between
normal and ischemic muscles. Statistically significant decrease in
PO2 in phosphate-buffered saline solution (PBS)–treated and
AdE1-treated ischemic animals; dose-dependent correction with
AdeNOS treatment. *P  .05 vs PBS; **P  .05 vs AdE1; #P 
.05 vs normal.
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NOS activity was significantly higher in AdeNOS-treated
rats than in AdE1-treated and PBS-treated rats at 3 and 14
days after gene transfer. By 30 days after gene transfer,
eNOS activity in AdeNOS-treated rats decreased to normal
levels (Fig 2, C).
Skeletal muscle blood flow and (PO2). Blood flow in
the gastrocnemius muscle, measured 14 days after gene
transfer, was significantly higher in AdeNOS-treated rats
(Fig 1, A). The flow rate of 2 mL/min/g of tissue achieved
in ischemic rats treated with AdeNOS is similar to the
maximal blood flow seen in nonischemic muscle when
stimulated with exercise.13 Resting blood flow was similar
in nonischemic muscle and ischemic muscle treated with
PBS or the control vector AdE1. We have demonstrated
previously that resting skeletal muscle blood flow is low and
requires exercise-induced hyperemia to demonstrate lack of
flow reserve in experimental chronic ischemia.13
While the rats were breathing room air, (PO2) of the left
gastrocnemius muscle was significantly higher in AdeNOS-
treated rats compared with PBS-treated or AdE1-treated
rats at all titers of AdeNOS except 5 108 plaque-forming
units (pfu)/mL (Fig 1, B). This increase persisted up to 30
days after gene transfer in rats receiving the highest dose of
AdeNOS (1  1010 pfu/mL). To unmask perfusion defi-
cits, rats were exposed to 100% inhaled oxygen.15,16 Tissue
PO2 in the ischemic left gastrocnemius muscle was signifi-
cantly higher in AdeNOS-treated rats than in AdE1-treated
rats at all titers (Fig 1, C). However, PO2 in AdeNOS-
treated rats was significantly higher than in PBS-treated rats
only at the highest titer of AdeNOS (147.3 19.6 mm Hg;
n  6; P  .05).
Cellular proliferation. To determine cellular prolifer-
ation in AdeNOS-treated rats, sections of muscle were
stained with BrdU. Despite the increase in blood flow and
tissue PO2 in AdeNOS-treated rats 14 days after gene
transfer, no difference in BrdU staining was found in the
calf muscles of experimental and control rats 5 days after
gene transfer (data not shown).
Histology and angiography. Gross and microscopic
examination of muscle did not reveal any evidence of
angioma or other arteriovenous malformation, as has been
described with VEGF overexpression.17 Thirty days after
gene transfer, the persistent increase in tissue oxygenation
after eNOS overexpression correlated with increased collat-
eral artery development and a trend toward increased cap-
illary–muscle fiber ratio. Capillary density was not signifi-
cantly higher in AdeNOS-treated rats compared with
control rats (data not shown). However, when capillary
counts were normalized per muscle fiber (capillary-fiber
ratios) to compensate for tissue edema and muscle atro-
phy,8 control rats had 1.8  0.3 capillaries per fiber and
AdeNOS-treated rats had 2.8  0.7 capillaries per fiber (P
 .08; Fig 3, A). Histologically, there was no difference in
number of arterioles in AdeNOS-treated rats compared
with control rats (data not shown). Contrast angiography
revealed significantly more collateral artery development in
AdeNOS-treated rats than in PBS-treated rats (Fig 3, B).
Fig 2. Transgene expression of endothelial nitric oxide synthase
(eNOS) after adenoviral-mediated gene transfer in ischemic hind
limbs. A, Western blot for eNOS protein on gastrocnemius muscle
homogenates 3 days after gene transfer of either AdE1 (control
vector) or adenoviral vector encoding eNOS (AdeNOS); graph of
densitometric analysis with Western blot (n  3 animals each). B,
Immunohistochemistry of cross-sectioned gastrocnemius muscle
with anti-eNOS antibody 3 days after gene transfer of either AdE1
or AdeNOS (80). C, Calcium-dependent NOS activity of muscle
homogenates at 3, 14, and 30 days after gene transfer. *P .05 vs
phosphate-buffered saline solution (PBS); **P  .05 vs AdE1.
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Mean angioscore was 4.5  0.5 in AdeNOS-treated rats
and 2.6  0.2 in control rats (P  .01; Fig 3, C).
DISCUSSION
We examined the effects of eNOS overexpression on
hind limb blood flow, muscle (PO2), and neovasculariza-
tion after induction of severe hind limb ischemia. Our
major findings were that intraarterial administration of
AdeNOS during vascular isolation results in increased NOS
activity up to 2 weeks after gene transfer; and that overex-
pression of eNOS increases resting skeletal muscle blood
flow to near maximal levels, increases (PO2) in the gastro-
cnemius muscle 1 month after gene transfer, and increases
collateral artery development, with a trend toward in-
creased capillary-fiber ratios.
Overexpression of eNOS in this study increased blood
flow fourfold and led to supranormal tissue (PO2), substan-
tially more than the 37% increase observed by Smith et al.18
The two studies were both performed with rat hind limb
ischemia models. However, they differ most notably in the
delivery technique used for adenovirus, intraarterial to the
calf in our study and intramuscular to the thigh in the study
by Smith et al18; by the different vectors, bovine eNOS
driven by the Rous sarcoma virus promoter and human
eNOS driven by the cytomegalovirus promoter; and possi-
bly by the level of eNOS overexpression induced.
Intra-arterial gene transfer results in greater adenoviral
transduction of the endothelium and adventitia of arteries,
arterioles, and capillaries than muscle fibers, whereas intra-
muscular delivery primarily transduces muscle fibers and
capillaries.14 This difference may account for the arterio-
genesis and lack of significant capillary angiogenesis seen in
our study. Our finding of increased blood flow and tissue
oxygenation without a significant change in capillary
counts indicates that the ability of NO to accelerate capil-
lary angiogenesis8,10 is not critical to its beneficial effects in
hind limb ischemia. Hershey et al19 also found that VEGF-
induced increases in blood flow in hind limb ischemia
correlated temporally with growth of large collateral vessels
rather than increases in capillary density. In addition, we
documented a threefold increase in eNOS activity, but
Smith et al18 did not measure in vivo increases in eNOS
activity. A more direct comparison of the levels of induced
eNOS activity might shed light on the differences between
the results of that study and our own. Both studies taken
together suggest that eNOS overexpression can drive both
capillary angiogenesis and arteriogenesis, but that intraar-
terial delivery may be better to drive arteriogenesis. This
interpretation is also suggested by our recent finding of
increased blood flow without significant capillary angio-
genesis after intraarterial delivery of an adeno-associated
virus, using the same model of rat hind limb ischemia.20
As opposed to the fourfold increase in blood flow we
observed after eNOS overexpression, either angiogenic
peptides or oral supplementation with L-arginine8,10 in-
creases ischemic-normal blood pressure ratio by 30% to
50% in the rabbit femoral artery excision model of hind
limb ischemia. These studies include intraarterial adminis-
tration of VEGF protein,4 intramuscular injection of VEGF
protein,5 intraarterial gene transfer of VEGF,6 gene transfer
of fibroblast growth factor,21 and hepatocyte growth fac-
tor.22 We measured regional blood flow rate and direct
muscle (PO2), and thus direct comparison with studies that
used indirect indices such as calf ischemic-normal blood
pressure ratio may be limited. Nonetheless, studies in which
Fig 3. Capillary–muscle fiber ratio and angiography after endo-
thelial nitric oxide (eNOS) overexpression. A, Trend toward in-
creased capillary–muscle fiber ratio 30 days after gene transfer (P
.08). B, More large collateral arteries were observed in adenoviral
eNOS (AdeNOS)–treated rats 30 days after gene transfer. Fewer
large collateral arteries were observed in phosphate-buffered saline
solution (PBS)–treated rats. C, Significantly higher angioscores in
AdeNOS-treated rats (n  7) vs PBS-treated rats (n  6). *P 
.001).
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both regional blood flow and calf blood pressure ratio were
measured can serve as a basis for this comparison. The
greater increases in blood flow after eNOS overexpression
compared with other molecules have important clinical
implications in reversing the effects of critical limb isch-
emia. Substantial and immediate increase in blood flow is
necessary to prevent limb loss.
Differences in degree of ischemia and local concentra-
tion of NO may account for the differing effects of eNOS
overexpression in our study and those that used L-arginine
supplementation or pharmacologic vasodilators. Tissue
hypoxia impairs endogenous eNOS enzyme activity,23 and
thus L-arginine supplementation may not be so effective as
overexpression of eNOS in improving collateral artery
growth and tissue perfusion.24 In chronic hypoxia, rat
arteries are dilated, VEGF is up-regulated, and production
of NO is stimulated. Increased permeability and angiogen-
esis help rats maintain tissue oxygen delivery and consump-
tion.25 The failure of sufficient collateral blood flow devel-
opment in patients with critical limb ischemia may be
related to eNOS dysfunction in these patients; this enzyme
dysfunction may also explain the lack of response to some
pharmacologic vasodilators.
The mechanism by which eNOS overexpression in-
creases blood flow and oxygenation may be multifactorial.
Increased blood flow with only a trend toward increased
capillary–muscle fiber ratio could be due to NO-induced
vasodilation, as noted in eNOS gene transfer studies, to
nonischemic hind limbs26 and in hind limbs with attenu-
ated vasodilatation after myocardial infarction.24 However,
we find this unlikely to be the sole mechanism, because
there was persistent increase in muscle oxygenation and
collateral artery development at 30 days (Fig 1) after NOS
activity had subsided to basal levels (Fig 2). Rather, we
suggest that eNOS overexpression leads to structural
changes in the hind limb vasculature and that the sustained
increase in tissue perfusion is not just from increased tonic
vasodilation by NO. Of note, NO induces both endothelial
cell migration and proliferation through the mitogen-
activated protein kinase pathway in vitro,27 and increase
VEGF secretion through the hypoxia response element.28
These nonvasodilatory functions of NO also support the
idea that eNOS overexpression could lead to structural
changes in the hind limb vasculature. Finally, release of NO
from the endothelium inhibits adhesion of platelets and
inflammatory cells; these anti-inflammatory and antithrom-
botic effects of NO may also contribute to the beneficial
effect of eNOS overexpression in hind limb ischemia.
We hypothesize that eNOS overexpression may in-
crease arteriogenesis via the following mechanism. Arterio-
lar vasodilation due to eNOS overexpression results in
decreased vascular resistance in the calf. Blood flow in-
creases through preformed collateral arteries in the thigh,
thereby inducing enlargement of these vessels via shear
stress–responsive arterial remodeling.19 The early phase of
the shear stress response consists of stimulation of endog-
enous eNOS to release increased NO, which in turn may
stimulate collateral artery development. This proposed
mechanism is consistent with our major findings, as well as
the lack of cellular proliferation in the calf at 5 days.
Blood flow rate of the gastrocnemius muscle in eNOS-
treated animals (2 mL/min/100 g of tissue) approached
flow rate induced by maximal exercise in nonischemic
limbs, not resting flow rate.13 Of no surprise, these rates of
blood flow induce PO2 greater than normal tissue PO2 of 40
mm Hg (Fig 1, A). Sustained supranormal tissue oxygen-
ation could lead to oxidant-mediated tissue injury; thus
optimal treatment of limb ischemia may use lower titers of
AdeNOS (ie, 5 108 pfu/mL; Fig 1, A). Lower adenoviral
titers are less likely to produce side effects, such as inflam-
mation caused by the adenoviral capsid protein, which can
cause dose-dependent gangrene.12
The finding that eNOS overexpression results in sub-
stantial, dose-dependent increases in blood flow and tissue
oxygenation without significant induction of capillary an-
giogenesis is novel and stands in contrast to the effects of
angiogenic peptides and dietary L-arginine supplementa-
tion. The rapid and substantial increases in skeletal muscle
blood flow and tissue oxygenation suggest that eNOS gene
transfer is a molecular therapy of potential value in treating
critical limb ischemia. Additional work on the exact mech-
anism or mechanisms by which eNOS overexpression in-
creases collateral artery development also remains to be
done. Impairment of eNOS function in many vascular
diseases, the critical role of NO in mediating VEGF-in-
duced angiogenesis, and the multiple beneficial effects of
NO in the vasculature make overexpression of this enzyme
a logical approach for treating critical limb ischemia.
We thank Beverly Davidson, from the University of
Iowa, for generously providing the AdE1 and AdeNOS
vectors.
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